BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018

BioTime, Inc. BTX, a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi Mohanty, Co-Chief Executive Officer, and Russell Skibsted, Chief Financial Officer, will host institutional investor and partnering meetings, at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

One-on-one meetings with Mr. Mohanty and/or Mr. Skibsted may be arranged by registering through LifeSci Advisors, LLC, by making a request via e-mail at Access@LifeSciAdvisors.com, or by contacting David Nakasone, Director of Investor Relations at BioTime, at 510-871-4188 or dnakasone@biotime.com.

About BioTime, Inc.

BioTime is a late-stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company's current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell and drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells, which can become any type of cell in the human body, and cell/drug delivery. Renevia^®, a cell delivery product, met its primary endpoint in an EU pivotal clinical trial for the treatment of facial lipoatrophy in HIV patients earlier this year. Submission for approval of Renevia^® in the EU is expected to be early 2018, with possible approval and commercial launch in 2018. There were no device related serious adverse events reported. OpRegen^®, a retinal pigment epithelium transplant therapy, is in a Phase I/IIa multicenter trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries. There were no related serious adverse events reported. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. AST and OncoCyte Corporation OCX, and a private company, AgeX Therapeutics, Inc.

BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

To receive ongoing BioTime corporate communications, please click on the following link to join the Company's email alert list: http://news.biotime.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171220005031/en/